Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The recommendations were made in a closed session with representatives from CBER, the CDC and Department of Defense.

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the ...

While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to ...

As Marty Makary and Jay Bhattacharya sail through the Senate health committee vote, Weldon's confirmation hearing is canceled ...

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...